A series of dinuclear ruthenium(II) complexes that contain labile chlorido ligands, [{Ru(tpy)Cl} 2 {m-bb n }] 2+ {designated Cl-Rubb n ; tpy = 2,2 0 :6 0 ,2 00 -terpyridine, bb n = bis[4(4 0 -methyl-2,2 0 -bipyridyl)]-1,n-alkane (n = 7, 10, 12, 14 or 16)} and derivatives containing nitro substituents on the tpy ligand and/or secondary amines within the bb n linking chain have been synthesised and their potential as anticancer agents examined. Some of the Cl-Rubb n species showed good anticancer activity against MCF-7 and MDA-MB-231 breast cancer cell lines, with the Cl-Rubb 12 complex being four-times more active than cisplatin.
{designated Cl-Rubb n ; tpy = 2,2 0 :6 0 ,2 00 -terpyridine, bb n = bis[4(4 0 -methyl-2,2 0 -bipyridyl)]-1,n-alkane (n = 7, 10, 12, 14 or 16)} and derivatives containing nitro substituents on the tpy ligand and/or secondary amines within the bb n linking chain have been synthesised and their potential as anticancer agents examined. Some of the Cl-Rubb n species showed good anticancer activity against MCF-7 and MDA-MB-231 breast cancer cell lines, with the Cl-Rubb 12 complex being four-times more active than cisplatin.
Inclusion of nitro substituents on the tpy ligands of Cl-Rubb 12 resulted in significantly decreased anticancer activity. The incorporation of amine groups into the linking ligand did not increase the anticancer activity of the Cl-Rubb n complexes. The Cl-Rubb n complexes and those containing amine groups in the linking chain aquated at approximately the same rate, with 50% aquation within 120 minutes.
By comparison, the complexes containing nitro substituents on the tpy ligand aquated extremely slowly, with 60% of the chlorido complex remaining 24 hours after they were dissolved in water. 
Introduction
Although cisplatin has been in clinical use for over 30 years, its toxicity and natural/acquired resistance to many cancers has considerably limited its application. 1 While some secondgeneration platinum complexes are less toxic than cisplatin, and others can partially overcome acquired resistance, there has been little success in developing drugs that are active in cancer cell lines resistant to cisplatin. Consequently, there has been considerable interest in the development of ''non-classical'' platinum complexes -complexes that can bind DNA in a different manner than cisplatin and its analogues. [2] [3] [4] [5] [6] [7] Multinuclear platinum complexes, where two or more platinum coordination units are linked by a variety of organic ligand bridges, represent a genuinely new class of anticancer drug. 2 While complexes with bi-functional platinum centres have been reported, those containing mono-functional coordinating spheres on the terminal platinum atoms (e.g. BBR 3005, see Fig. 1 ) gave the most encouraging results. [8] [9] [10] [11] Furthermore, complexes bearing a cationic charge and hydrogen-bonding capacity (e.g. amine groups or inert am(m)ineplatinum(II) centres) in the linking ligand were shown to be the most active in both cisplatin-sensitive and -resistant cell lines. 12 While the multinuclear platinum complexes are highly cytotoxic, they are also highly toxic. 13, [23] [24] [25] [26] Furthermore, upon administration they bind thiol-containing plasma proteins in the bloodstream, and are subsequently degraded to non-active metabolites. Although BBR 3464 has been withdrawn from 30 In this present study we sought to extend the family of Cl-Rubb n dinuclear complexes by using a similar approach to that of Farrell and co-workers for the multinuclear platinum complexes. 2,9-11 Consequently, we have synthesised and examined the anticancer activities, rates of hydrolysis, and binding ability to guanosine 5 0 -monophosphate (GMP) of a series of Cl-Rubb n complexes that contain cationic groups (NH 2 + ) in the chain of the bb n linking ligand (Cl-RubbN n ). Furthermore, in order to determine the effect of changes in charge distribution (and hence, the rate of ligand exchange) on the ruthenium(II) complexes, we have prepared several Cl-Rubb n and Cl-RubbN n complexes that contain three electronwithdrawing NO 2 groups on the tpy ligands (Cl-Rubb n NO 2 and Cl-RubbN n NO 2 ). Fig. 3 ). The aquation then proceeds to equilibrium, where approximately 90% of the ruthenium complex exists in the aqua form. The inclusion of amine groups into the linking ligand had no significant effect on the rate or equilibrium position of aquation. peak corresponding to the Ru(III/II) couple is shifted positively by at least 300 mV, to the point where it coincides with oxidation of the chloride counter-ion (and is irreversible). This large positive shift indicates that the nitro substituents cause a significant decrease in the electron density on the ruthenium centre, making oxidation to Ru(III) more difficult.
Results

Synthesis
Discussion
The decreased the activity, whereas it had little effect on the activity of Cl-Rubb 16 .
In previous studies with chlorido-containing dinuclear ruthenium(II) complexes, 27, 28, 30, 40 the cytotoxicity has always increased as the number of methylene groups in the flexible alkane chain increased. Interestingly, in the present study the Cl-Rubb 16 complex was the least active of the Cl-Rubb n complexes. The decreased activities of Cl-Rubb 7 and Cl-Rubb 16 , compared to Cl-Rubb 12 suggest two competing factors govern the anticancer activity. While it is yet to be confirmed, it is assumed that the major mechanism of anticancer activity is related to DNA binding, analogous to the corresponding dinuclear platinum complexes. Increasing the number of methylene groups in the linking chain should increase the lipophilicity of the dinuclear complex, and hence the ease with which it can pass through the cellular membrane. While aquation is the necessary first step in DNA binding, as determined by the GMP binding experiments, all the Cl-Rubb n complexes exhibited similar rates of aquation and percentage of the aqua form at equilibrium. Consequently, the relative cytotoxicity results could imply that the range of possible DNA cross-linked adducts formed have significantly different biological outcomes, and/or the anticancer activity is controlled by both covalent and reversible binding to DNA. For the corresponding inert Rubb n complexes, the DNA binding affinity decreases with increasing methylene groups in the linking chain. 41 Furthermore, based purely upon polycation condensation of polyanionic DNA, it would also be expected that the cytotoxicity of the Cl-Rubb n complexes would decrease with increasing chain length. The inclusion of three nitro substituents on the tpy ligand significantly increased the IC 50 value for the more cytotoxic Cl-Rubb 12 increase the energy barrier for the removal of the chlorido ligand from the metal centre, thereby decreasing the rate of the aquation reaction. Aquation was shown to be the first step in the coordination of the ruthenium complexes with DNA. Consequently, the Cl-Rubb n NO 2 complexes would not form as many covalent adducts with DNA over the time period of the cytotoxicity assays, compared to their non-nitrated parent complexes. This suggests that the observed cytotoxicity of the Cl-Rubb n NO 2 complexes would largely be due to their reversible, non-covalent, binding to DNA. Furthermore, it is reasonable to expect that the chlorido form of the complex would more easily cross a cellular membrane than the more highly positivelycharged aquated species. Based upon these assumptions, it could be tentatively concluded that the activity of Cl-Rubb 16 was predominantly due to reversible binding to DNA, while the activity of Cl-Rubb 12 was due to a combination of covalent and reversible binding to DNA. Although the inclusion of one or more secondary amines into the bridging ligand of multinuclear platinum complexes significantly increases their cytotoxicity, 2 the incorporation of amine groups into the ligand bridge of Cl-Rubb n did not increase the cytotoxicity. For the multinuclear platinum complexes, incorporation of an amine group or an inert am(m)-ineplatinum(II) centre into the bridge enhances cellular accumulation and increases the affinity for DNA. 2, 14, 42 The corresponding inert Rubb n dinuclear ruthenium complexes (that do not contain labile chlorido ligands) enter L1210 murine leukaemia cells by passive diffusion, with a minor contribution from proteinmediated active transport. 41 Consequently, incorporation of amine groups into the ligand bridge could decrease the cellular uptake of the Cl-Rubb n complexes, and thereby result in the observed lower activity for Cl-RubbN 7 relative to Cl-Rubb 7 . However, it was also noted that Cl-RubbN 16 was equally as active (albeit weakly) as Cl-Rubb 16 . This could suggest that the inclusion of an amine in the bridging ligand of a Cl-Rubb n complex does increase the reversible binding affinity for DNA, thereby compensating for the lower cellular uptake.
Conclusions
In conclusion, the results of this study support the idea of developing a new class of anticancer agent by transferring from platinum to ruthenium the concept of gaining advantages in efficacy through the use of multinuclear complexes, as proposed by Mendoza-Ferri et al. 27 Dinuclear ruthenium complexes -containing
This journal is © The Royal Society of Chemistry and the Centre National de la Recherche Scientifique 2014 a single chlorido ligand on each metal centre -were synthesised and found to be significantly more active than cisplatin against two breast cancer cell lines. The anticancer activity appears to be due to a combination of covalent and reversible binding with DNA. The IC 50 results indicated that the Cl-Rubb 12 complex was the most active of the dinuclear complexes. The superior activity of Cl-Rubb 12 might be due to the best compromise between lipophilicity (for cellular uptake) and the cytotoxic effects of the covalent adducts formed with DNA. Given the vast array of ligands that can be utilised for the Cl-Rubb n complexes, it should be possible to optimise cellular uptake and the kinetics of DNA binding, and thereby produce dinuclear ruthenium(II) complexes with significant clinical potential.
Experimental
Physical measurements 
Cyclic voltammetry
Cyclic voltammetry was carried out using an eDAQ EA161 potentiostat operated via an eDAQ ED401 e-corder. A glassy carbon working electrode, platinum wire counter electrode and Ag/AgCl reference electrode were used. HPLC grade acetonitrile was used as solvent and the supporting electrolyte was 0.1 mol L À1 tetra-n-butyl ammonium hexafluorophosphate (Aldrich).
Cytotoxicity assays
Cytotoxicity data was obtained using the mitochondrialdependent reduction of 3-(3,4-dimethylthiazol-2yl)-5-diphenyl tetrazolium bromide (MTT) to formazan as described by Guh et al. 43 Metal complex solutions, including the control platinum complexes cisplatin and carboplatin, were made to the required concentrations in warm Milli-Q water. Growth inhibition assays were carried out over a 72 h continuous exposure period. trichloride (15 mL) was refluxed for 18 h under an Ar atmosphere, and the hot solution was then poured on ice and made alkaline with 40% ammonium hydroxide solution. The precipitate was filtered, dried under vacuum, and crystallised from benzene to obtain 0.64 g of the pure product (yield 56%). 7 mmol) were refluxed in 1,4-dioxane (45 mL) under a N 2 atmosphere for 24 h. The solution was filtered while hot to remove the solid selenium and the filtrate allowed to stand at room temperature for 1 h and then evaporated to obtain a pale pink powder. This crude product was redissolved in ethyl acetate (150 mL), the undissolved solid was removed by filtration and the filtrate was evaporated to obtain pale yellow solid. The crude product was dissolved in minimal volume of DCM and impregnated with silica gel (230-400 mesh, 5 g) the impregnated mixture was then loaded on a silica gel column (230-400 mesh; 3 cm diam. Â 15 cm), the unreacted Me 2 bpy was eluted with 5% (v/v) ethyl acetate in n-hexane and the product was eluted using 20-30% (v/v) ethyl acetate in n-hexane. The purity of each fraction was monitored by TLC, using 30% (v/v) ethyl acetate in n-hexane as the mobile phase. The purest fractions were combined and the solvent was evaporated in vacuo to obtain white solid. A final recrystallisation with n-pentane gave 0.82 g of the pure product as a white powder (yield 38% was then added to the reaction mixture and stirred at 65 1C for 1-2 h. The solvent was evaporated from the reaction mixture and water (10 mL) added to the crude residue. The organic component was extracted with dichloromethane (3 Â 50 mL), and the organic phase was then washed with water (20 mL) and brine (20 mL). After removing the solvent, the crude residue was purified by column chromatography using silica gel, the unreacted starting material and other impurities were eluted 
Synthesis of ligands
). 1 H NMR (400 MHz, CDCl 3 ): d 10.17 (s, 1H); 8.89 (d, J = 5.
Synthesis of metal complexes
[{Ru(tpy)Cl} 2 {m-bb n }] 2+ (Cl-Rubb n ). The ruthenium(II) complexes Cl-Rubb n were synthesised using a slight modification of methods previously described.
30
[Ru{(NO 2 ) 3 tpy}Cl 3 ]. 4,4 0 ,4 00 -Trinitro-2,2 0 :6 0 ,2 00 -terpyridine (0.44 g, 1.7 mmol) was stirred in absolute ethanol (220 mL) with gentle heating until dissolution. RuCl 3 Á3H 2 O (0.63 g, 1.7 mmol) was added and the solution refluxed for 3 h with stirring under nitrogen atmosphere. After the mixture was cooled to room temperature, the violet brown precipitate was filtered, washed with excess of ethanol and ether, and dried under vacuum to yield 0.58 g of the product (yield 59%). After cooling, the solvent mixture was evaporated to approximately half of the original volume and saturated aqueous NH 4 PF 6 was added slowly to precipitate a dark violet-purple material, which was filtered and washed with ethanol (2 Â 15 mL) followed by diethyl ether (2 Â 15 mL). The crude product was dissolved in a minimum amount of acetone and loaded onto a column of Sephadex LH-20 (2 cm diam. Â 30 cm), and using acetone as the eluent, the major first band was collected and acetone was evaporated to obtain [Ru{(NO 2 ) 3 The chloride salts were obtained by stirring the PF 6 salt in water using Amberlite IRA-400 (chloride form) anion-exchange resin. The resin was removed by filtration, and the solution was freeze-dried to obtain a fluffy dark violet-purple powder of pure [{Ru(NO 2 terpy)(Cl)} 2 (m-bb n )]Cl 2 in 30-35% yield.
[{Ru(tpy)Cl} 2 (m-bbH 2 
